8. Huntington disease Clinical trials / Disease details
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-000105-92-LT (EUCTR) | 02/03/2022 | 28/10/2021 | A study to evaluate the safety, tolerability and efficacy of weekly oral doses of branaplam in patients with Huntington's Disease | A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study with Open-Label Extension to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LMI070/branaplam when Administered as Weekly Oral Doses in Participants with Early Manifest Huntington’s Disease | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: branaplam Product Code: LMI070 INN or Proposed INN: BRANAPLAM | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2 | France;United States;Hungary;Canada;Spain;Belgium;Lithuania;Russian Federation;Germany;United Kingdom;Italy | ||
| 2 | NCT05111249 (ClinicalTrials.gov) | December 8, 2021 | 15/10/2021 | A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease | A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study With Open-Label Extension to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of LMI070/Branaplam Administered as Weekly Oral Doses in Participants With Early Manifest Huntington's Disease | Early Manifest Huntington Disease | Drug: Branaplam;Drug: Placebo | Novartis Pharmaceuticals | NULL | Active, not recruiting | 25 Years | 75 Years | All | 75 | Phase 2 | United States;Belgium;Canada;France;Germany;Hungary;Italy;Spain;United Kingdom |
| 3 | EUCTR2020-000105-92-IT (EUCTR) | 26/11/2021 | 20/09/2021 | A study to evaluate the safety, tolerability and efficacy of weekly oral doses of branaplam in patients with Huntington's Disease | A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study with Open-Label Extension to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LMI070/branaplam when Administered as Weekly Oral Doses in Participants with Early Manifest Huntington's Disease - - | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: branaplam Product Code: [LMI070] INN or Proposed INN: BRANAPLAM Product Name: branaplam Product Code: [LMI070] INN or Proposed INN: BRANAPLAM Product Name: branaplam Product Code: [LMI070] INN or Proposed INN: BRANAPLAM Product Name: branaplam Product Code: [LMI070] INN or Proposed INN: BRANAPLAM Product Name: branaplam Product Code: [LMI070] INN or Proposed INN: BRANAPLAM | NOVARTIS PHARMA AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2 | France;United States;Hungary;Canada;Spain;Belgium;Lithuania;Russian Federation;Germany;United Kingdom;Italy | ||
| 4 | EUCTR2020-000105-92-FR (EUCTR) | 18/11/2021 | 03/09/2021 | A study to evaluate the safety, tolerability and efficacy of weekly oral doses of branaplam in patients with Huntington's Disease | A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study with Open-Label Extension to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LMI070/branaplam when Administered as Weekly Oral Doses in Participants with Early Manifest Huntington’s Disease | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: branaplam Product Code: LMI070 INN or Proposed INN: BRANAPLAM | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2 | Spain;Belgium;Lithuania;Russian Federation;Germany;United Kingdom;Italy;United States;France;Hungary;Canada | ||
| 5 | EUCTR2020-000105-92-ES (EUCTR) | 02/11/2021 | 26/08/2021 | A study to evaluate the safety, tolerability and efficacy of weekly oral doses of branaplam in patients with Huntington's Disease | A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study with Open-Label Extension to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LMI070/branaplam when Administered as Weekly Oral Doses in Participants with Early Manifest Huntington’s Disease | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: branaplam Product Code: LMI070 INN or Proposed INN: BRANAPLAM | Novartis Farmacéutica S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2 | France;United States;Hungary;Canada;Belgium;Spain;Lithuania;Russian Federation;Germany;United Kingdom;Italy | ||
| 6 | EUCTR2020-000105-92-HU (EUCTR) | 29/10/2021 | 24/08/2021 | A study to evaluate the safety, tolerability and efficacy of weekly oral doses of branaplam in patients with Huntington's Disease | A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study with Open-Label Extension to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LMI070/branaplam when Administered as Weekly Oral Doses in Participants with Early Manifest Huntington’s Disease | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: branaplam Product Code: LMI070 INN or Proposed INN: BRANAPLAM | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2 | France;United States;Hungary;Canada;Belgium;Spain;Lithuania;Russian Federation;Germany;United Kingdom;Italy | ||
| 7 | EUCTR2020-000105-92-DE (EUCTR) | 15/10/2021 | 18/08/2021 | A study to evaluate the safety, tolerability and efficacy of weekly oral doses of branaplam in patients with Huntington's Disease | A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study with Open-Label Extension to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LMI070/branaplam when Administered as Weekly Oral Doses in Participants with Early Manifest Huntington’s Disease | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: branaplam Product Code: LMI070 INN or Proposed INN: BRANAPLAM | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2 | United States;France;Hungary;Canada;Spain;Belgium;Lithuania;Russian Federation;Germany;United Kingdom;Italy |